This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Mumps virus strain B level jeryl lynn live antigen is a vaccine used to prevent Mumps.

Brand Names
M-M-R II, Proquad
Generic Name
Mumps virus strain B level jeryl lynn live antigen
DrugBank Accession Number
DB10316
Background

Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Mumps virus vaccine live attenuated (Jeryl Lynn strain)
  • Mumps Virus Vaccine Live, Jeryl Lynn Strain

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MumpsvaxPowder, for solution5000 unit / 0.5 mLSubcutaneousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1969-12-312004-08-27Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
M-M-R IIMumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.1979-12-31Not applicableCanada flag
M-M-R IIMumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousA-S Medication Solutions1971-04-21Not applicableUS flag
M-M-R IIMumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousPhysicians Total Care, Inc.1996-08-072012-06-30US flag
M-M-R IIMumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.1971-04-21Not applicableUS flag
M-M-R II VACCINEMumps virus strain B level jeryl lynn live antigen (12500 CCID50/0.5mL) + Measles virus vaccine live attenuated (1000 CCID50/0.5mL) + Rubella virus vaccine (1000 CCID50/0.5mL)Injection, powder, for solutionSubcutaneousMSD PHARMA (SINGAPORE) PTE. LTD.1988-06-24Not applicable
M-M-rvaxproMumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproMumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproMumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproMumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproMumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50)Msd Vaccins2021-02-10Not applicableEU flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
47QB6MX9KU
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910495
RxNav
798372

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableRheumatoid Arthritis, Juvenile1
4CompletedPreventionAdverse Event Following Immunization / Measles / Mumps / Rubella1
4CompletedPreventionBCG Infection / Immune Responses / Vaccine Reaction1
4CompletedPreventionChickenpox / Hepatitis A / Measles / Mumps / Rubella1
4CompletedPreventionEncephalitis, Japanese B / Measles / Mumps / Rubella1
4CompletedPreventionHepatitis A Virus1
4CompletedPreventionHepatitis A / Measles / Mumps / Rubella1
4CompletedPreventionMeasles / Mumps / Rubella2
4CompletedPreventionMumps1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionSubcutaneous
Injection, powder, lyophilized, for suspensionSubcutaneous
Injection, powder, for solutionSubcutaneous1000 CCID50/0.5mL
Injection, powder, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous
Powder, for solutionSubcutaneous5000 unit / 0.5 mL
Injection, powder, for solutionSubcutaneous
Kit; powder, for solutionIntramuscular; Subcutaneous
Injection, solutionIntramuscular; Subcutaneous
Injection, powder, for solutionIntramuscular; Subcutaneous
Injection, powder, for solutionIntramuscular; Subcutaneous1000 TCID50/0.5ml
Injection
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous1000 CCID50
Powder, for solutionIntramuscular; Subcutaneous
Powder, for solutionSubcutaneous
Injection, powder, lyophilized, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for solutionSubcutaneous3 log10 tcid50/0.5mL
InjectionSubcutaneous
Solution
Injection, powder, lyophilized, for suspension
Powder
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:03 / Updated at January 25, 2022 05:26